NCT07025148View on ClinicalTrials.gov

Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

August 1, 2027

Study Completion Date

November 1, 2027

Conditions
Coronary Arterial Disease (CAD)Percutaneous Coronary Intervention (PCI)
Interventions
DRUG

Prasugrel

Prasugrel 5 mg od for 30 ± 5 days

DRUG

Clopidogrel

Clopidogrel 75 mg od for 30 ± 5 days

Trial Locations (1)

32209

University of Florida Health, Jacksonville

All Listed Sponsors
lead

University of Florida

OTHER